NT2 (NexThera Co., Ltd.)

NT2 is a preclinical drug candidate developed by NexThera for the treatment of solid tumors. It is the lead candidate in NexThera's 'cancer cell-selective protein synthesis inhibition' program, which is based on the 'Strong mRNA / weak mRNA hypothesis.' This strategy posits that cancer cells are disproportionately dependent on the translation of 'weak' mRNAs—those with complex 5' untranslated regions (UTRs) that encode critical oncogenic proteins like c-Myc, Cyclin D1, and VEGF. NT2 is designed to selectively inhibit the protein translation initiation complex (eIF4F) or its regulatory pathways, thereby suppressing the production of these oncogenic proteins while sparing normal cellular translation. The drug utilizes NexThera's proprietary recombinant protein and peptide-based platform to achieve targeted delivery and selective action within the tumor microenvironment.